These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8687147)

  • 1. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
    Lindmark G; Kressner U; Bergström R; Glimelius B
    Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum markers in carcinoma of the rectum and rectosigmoid. I. Prediction of tumour stage.
    Ståhle E; Glimelius B; Bergström R; Påhlman L
    Eur J Surg Oncol; 1988 Aug; 14(4):277-86. PubMed ID: 3165869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum markers in carcinoma of the rectum and rectosigmoid. II. Prediction of prognosis.
    Ståhle E; Glimelius B; Bergström R; Påhlman L
    Eur J Surg Oncol; 1988 Aug; 14(4):287-96. PubMed ID: 3165870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer.
    Iizasa T; Suzuki M; Yoshida S; Motohashi S; Yasufuku K; Iyoda A; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T
    Ann Thorac Surg; 2006 Jul; 82(1):254-60. PubMed ID: 16798225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin-6 levels reflect the disease status of colorectal cancer.
    Chung YC; Chang YF
    J Surg Oncol; 2003 Aug; 83(4):222-6. PubMed ID: 12884234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
    Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
    Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
    Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
    Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer.
    Carpelan-Holmström MA; Haglund CH; Järvinen HJ; Roberts PJ
    Anticancer Res; 1996; 16(2):981-6. PubMed ID: 8687164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
    Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.